ASUS VivoWatch ECG App Receives FDA Thailand Certification

TAIPEI, Taiwan, July 1, 2025 — ASUS today announced that the VivoWatch ECG app has been certified by the Food and Drug Administration Thailand (FDA Thai). A major advancement for smart healthcare innovation in Thailand, certification for the ECG software marks a milestone for ASUS, underscoring its expanding role in the global digital health landscape and its commitment to medical-grade technology innovation.  

ʺOur goal is to empower individuals and healthcare providers with the best health monitoring tools,ʺ said Joe Hsieh, COO and Global Senior Vice President of ASUS. ʺThis certification validates our technology and also reinforces the ASUS commitment to expanding global access to smart, medical-grade health solutions.ʺ  

With the new ECG app, users can measure their ECG readings directly via ASUS VivoWatch. To take a measurement, the user places a fingertip on the watch–face sensors for 30 seconds. It will display the results and even allow users to easily share them with their healthcare provider. Compatible ASUS VivoWatch models include the latest ASUS VivoWatch 6 and ASUS VivoWatch 6 AERO.  

The ECG functionality enabled by ASUS VivoWatch is ideal for individual consumers as well as for use in hospitals, clinics and any other healthcare setting. It can also be integrated into business-to-business (B2B) solutions to enhance VIP patient care and support premium health management services.  

In addition to the newly activated ECG function, ASUS VivoWatch also supports blood pressure monitoring. This means that VivoWatch enables users to track two essential cardiovascular indicators simultaneously. With accurate, real-time date, the solution helps detect potential health issues, making it a valuable asset for institutions aiming to improve both care quality and operational efficiency.    

To enjoy the benefits of the accurate ECG feature today, users simply need to update both the ASUS HealthConnect app and the ASUS VivoWatch software.